Another study revealed that tumors carrying mutated EGFR tended to have low PD-L1 and CD8 + T cell levels, resulting in weaker immunogenicity.[25] This may partially explain why NSCLC patients with mutant EGFR respond poorly to ICIs. This evidence concerns the gene CD8A and non-small cell lung carcinoma.